NewAmsterdam Pharma Ownership 2024 | Who Owns NewAmsterdam Pharma Now?
Institutional Ownership
100.00%
Insider Ownership
0.26%
Retail Ownership
-0.26%
Institutional Holders
20.00
NewAmsterdam Pharma Institutional Shareholders
Institutional Shareholders by % of Total Shares
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 82.48% | 9.09% | 9,341,551 | - | - | 125,550,445,000 | Mar 31, 2023 |
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC | 73.29% | 13.76% | 8,300,000 | - | - | 110,058,000 | Mar 31, 2023 |
RA CAPITAL MANAGEMENT, L.P. | 35.32% | 1.20% | 4,000,000 | - | - | 53,040,000,000 | Mar 31, 2023 |
VIKING GLOBAL INVESTORS LP | 34.58% | 0.25% | 3,915,870 | 162,042 | 4.32% | 52,629,293,000 | Mar 31, 2023 |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 22.39% | 0.75% | 2,535,723 | 55,524 | 2.24% | 33,623,687,000 | Mar 31, 2023 |
MEDICXI VENTURES MANAGEMENT (JERSEY) LTD | 17.66% | 11.36% | 2,000,000 | - | - | 26,520,000,000 | Mar 31, 2023 |
BVF INC/IL | 13.44% | 0.75% | 1,521,948 | - | - | 20,454,981,000 | Mar 31, 2023 |
GMT CAPITAL CORP | 9.57% | 0.56% | 1,083,800 | 83,800 | 8.38% | 14,371,188,000 | Mar 31, 2023 |
ENSIGN PEAK ADVISORS, INC | 3.13% | 0.01% | 355,000 | - | - | 4,707,300,000 | Mar 31, 2023 |
ALYESKA INVESTMENT GROUP, L.P. | 2.55% | 0.03% | 289,265 | 289,265 | 100.00% | 3,835,654,000 | Mar 31, 2023 |
PARKMAN HEALTHCARE PARTNERS LLC | 1.02% | 0.33% | 115,000 | 115,000 | 100.00% | 1,524,900,000 | Mar 31, 2023 |
MILLENNIUM MANAGEMENT LLC | 0.49% | 0.00% | 55,633 | 55,633 | 100.00% | 748,000 | Mar 31, 2023 |
EVERSEPT PARTNERS, LP | 0.40% | 0.05% | 45,856 | 45,856 | 100.00% | 608,051,000 | Mar 31, 2023 |
SCHONFELD STRATEGIC ADVISORS LLC | 0.27% | 0.00% | 30,100 | 30,100 | 100.00% | 399,126,000 | Mar 31, 2023 |
JPMORGAN CHASE & CO | 0.20% | - | 22,367 | 21,265 | 1929.67% | 301,000,000 | Mar 31, 2023 |
GEODE CAPITAL MANAGEMENT, LLC | 0.16% | - | 18,559 | 18,559 | 100.00% | 249,432,000 | Mar 31, 2023 |
MINT TOWER CAPITAL MANAGEMENT B.V. | 0.06% | 0.00% | 6,533 | 6,533 | 100.00% | 12,000 | Mar 31, 2023 |
WOLVERINE ASSET MANAGEMENT LLC | 0.04% | 0.00% | 4,819 | 4,819 | 100.00% | 63,899,000 | Mar 31, 2023 |
MORGAN STANLEY | 0.00% | - | 503 | 503 | 100.00% | 6,670,000 | Mar 31, 2023 |
ATTICUS WEALTH MANAGEMENT, LLC | 0.00% | 0.00% | 166 | 166 | 100.00% | 2,202,000 | Mar 31, 2023 |
NewAmsterdam Pharma's largest institutional shareholder is FRAZIER LIFE SCIENCES MANAGEMENT, L.P., holding 82.48% of the company's total share outstanding, currently valued at $125.55B. The top 10 institutional shareholders own together 294.41% of the company.
Institutional Shareholders by % of Total Assets
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC | 73.29% | 13.76% | 8,300,000 | - | - | 110,058,000 | Mar 31, 2023 |
MEDICXI VENTURES MANAGEMENT (JERSEY) LTD | 17.66% | 11.36% | 2,000,000 | - | - | 26,520,000,000 | Mar 31, 2023 |
FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 82.48% | 9.09% | 9,341,551 | - | - | 125,550,445,000 | Mar 31, 2023 |
RA CAPITAL MANAGEMENT, L.P. | 35.32% | 1.20% | 4,000,000 | - | - | 53,040,000,000 | Mar 31, 2023 |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 22.39% | 0.75% | 2,535,723 | 55,524 | 2.24% | 33,623,687,000 | Mar 31, 2023 |
BVF INC/IL | 13.44% | 0.75% | 1,521,948 | - | - | 20,454,981,000 | Mar 31, 2023 |
GMT CAPITAL CORP | 9.57% | 0.56% | 1,083,800 | 83,800 | 8.38% | 14,371,188,000 | Mar 31, 2023 |
PARKMAN HEALTHCARE PARTNERS LLC | 1.02% | 0.33% | 115,000 | 115,000 | 100.00% | 1,524,900,000 | Mar 31, 2023 |
VIKING GLOBAL INVESTORS LP | 34.58% | 0.25% | 3,915,870 | 162,042 | 4.32% | 52,629,293,000 | Mar 31, 2023 |
EVERSEPT PARTNERS, LP | 0.40% | 0.05% | 45,856 | 45,856 | 100.00% | 608,051,000 | Mar 31, 2023 |
ALYESKA INVESTMENT GROUP, L.P. | 2.55% | 0.03% | 289,265 | 289,265 | 100.00% | 3,835,654,000 | Mar 31, 2023 |
ENSIGN PEAK ADVISORS, INC | 3.13% | 0.01% | 355,000 | - | - | 4,707,300,000 | Mar 31, 2023 |
SCHONFELD STRATEGIC ADVISORS LLC | 0.27% | 0.00% | 30,100 | 30,100 | 100.00% | 399,126,000 | Mar 31, 2023 |
MINT TOWER CAPITAL MANAGEMENT B.V. | 0.06% | 0.00% | 6,533 | 6,533 | 100.00% | 12,000 | Mar 31, 2023 |
ATTICUS WEALTH MANAGEMENT, LLC | 0.00% | 0.00% | 166 | 166 | 100.00% | 2,202,000 | Mar 31, 2023 |
WOLVERINE ASSET MANAGEMENT LLC | 0.04% | 0.00% | 4,819 | 4,819 | 100.00% | 63,899,000 | Mar 31, 2023 |
MILLENNIUM MANAGEMENT LLC | 0.49% | 0.00% | 55,633 | 55,633 | 100.00% | 748,000 | Mar 31, 2023 |
JPMORGAN CHASE & CO | 0.20% | - | 22,367 | 21,265 | 1929.67% | 301,000,000 | Mar 31, 2023 |
GEODE CAPITAL MANAGEMENT, LLC | 0.16% | - | 18,559 | 18,559 | 100.00% | 249,432,000 | Mar 31, 2023 |
MORGAN STANLEY | 0.00% | - | 503 | 503 | 100.00% | 6,670,000 | Mar 31, 2023 |
The largest NewAmsterdam Pharma shareholder by % of total assets is BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC. The company owns 8.30M shares of NewAmsterdam Pharma (NAMS), representing 13.76% of its total assets.
Institutional Buyers
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
ALYESKA INVESTMENT GROUP, L.P. | 2.55% | 0.03% | 289,265 | 289,265 | 100.00% | 3,835,654,000 | Mar 31, 2023 |
VIKING GLOBAL INVESTORS LP | 34.58% | 0.25% | 3,915,870 | 162,042 | 4.32% | 52,629,293,000 | Mar 31, 2023 |
PARKMAN HEALTHCARE PARTNERS LLC | 1.02% | 0.33% | 115,000 | 115,000 | 100.00% | 1,524,900,000 | Mar 31, 2023 |
GMT CAPITAL CORP | 9.57% | 0.56% | 1,083,800 | 83,800 | 8.38% | 14,371,188,000 | Mar 31, 2023 |
MILLENNIUM MANAGEMENT LLC | 0.49% | 0.00% | 55,633 | 55,633 | 100.00% | 748,000 | Mar 31, 2023 |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 22.39% | 0.75% | 2,535,723 | 55,524 | 2.24% | 33,623,687,000 | Mar 31, 2023 |
EVERSEPT PARTNERS, LP | 0.40% | 0.05% | 45,856 | 45,856 | 100.00% | 608,051,000 | Mar 31, 2023 |
SCHONFELD STRATEGIC ADVISORS LLC | 0.27% | 0.00% | 30,100 | 30,100 | 100.00% | 399,126,000 | Mar 31, 2023 |
JPMORGAN CHASE & CO | 0.20% | - | 22,367 | 21,265 | 1929.67% | 301,000,000 | Mar 31, 2023 |
GEODE CAPITAL MANAGEMENT, LLC | 0.16% | - | 18,559 | 18,559 | 100.00% | 249,432,000 | Mar 31, 2023 |
MINT TOWER CAPITAL MANAGEMENT B.V. | 0.06% | 0.00% | 6,533 | 6,533 | 100.00% | 12,000 | Mar 31, 2023 |
WOLVERINE ASSET MANAGEMENT LLC | 0.04% | 0.00% | 4,819 | 4,819 | 100.00% | 63,899,000 | Mar 31, 2023 |
MORGAN STANLEY | 0.00% | - | 503 | 503 | 100.00% | 6,670,000 | Mar 31, 2023 |
ATTICUS WEALTH MANAGEMENT, LLC | 0.00% | 0.00% | 166 | 166 | 100.00% | 2,202,000 | Mar 31, 2023 |
DUPONT CAPITAL MANAGEMENT CORP | - | - | 1 | - | - | 13,000 | Mar 31, 2023 |
ENSIGN PEAK ADVISORS, INC | 3.13% | 0.01% | 355,000 | - | - | 4,707,300,000 | Mar 31, 2023 |
BVF INC/IL | 13.44% | 0.75% | 1,521,948 | - | - | 20,454,981,000 | Mar 31, 2023 |
RA CAPITAL MANAGEMENT, L.P. | 35.32% | 1.20% | 4,000,000 | - | - | 53,040,000,000 | Mar 31, 2023 |
FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 82.48% | 9.09% | 9,341,551 | - | - | 125,550,445,000 | Mar 31, 2023 |
MEDICXI VENTURES MANAGEMENT (JERSEY) LTD | 17.66% | 11.36% | 2,000,000 | - | - | 26,520,000,000 | Mar 31, 2023 |
As of Mar 31 2023, NewAmsterdam Pharma's largest institutional buyer is ALYESKA INVESTMENT GROUP, L.P.. The company purchased 289.26K stocks of NAMS, valued at $3.84B.
Institutional Sellers
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
JANUS HENDERSON GROUP PLC | - | - | - | -563,119 | -100.00% | - | Mar 31, 2023 |
ALYESKA INVESTMENT GROUP, L.P. | - | - | - | -200,000 | -100.00% | - | Mar 31, 2023 |
TOWER RESEARCH CAPITAL LLC (TRC) | - | - | - | -88 | -100.00% | - | Mar 31, 2023 |
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC | 73.29% | 13.76% | 8,300,000 | - | - | 110,058,000 | Mar 31, 2023 |
MEDICXI VENTURES MANAGEMENT (JERSEY) LTD | 17.66% | 11.36% | 2,000,000 | - | - | 26,520,000,000 | Mar 31, 2023 |
FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 82.48% | 9.09% | 9,341,551 | - | - | 125,550,445,000 | Mar 31, 2023 |
RA CAPITAL MANAGEMENT, L.P. | 35.32% | 1.20% | 4,000,000 | - | - | 53,040,000,000 | Mar 31, 2023 |
BVF INC/IL | 13.44% | 0.75% | 1,521,948 | - | - | 20,454,981,000 | Mar 31, 2023 |
ENSIGN PEAK ADVISORS, INC | 3.13% | 0.01% | 355,000 | - | - | 4,707,300,000 | Mar 31, 2023 |
DUPONT CAPITAL MANAGEMENT CORP | - | - | 1 | - | - | 13,000 | Mar 31, 2023 |
ATTICUS WEALTH MANAGEMENT, LLC | 0.00% | 0.00% | 166 | 166 | 100.00% | 2,202,000 | Mar 31, 2023 |
MORGAN STANLEY | 0.00% | - | 503 | 503 | 100.00% | 6,670,000 | Mar 31, 2023 |
WOLVERINE ASSET MANAGEMENT LLC | 0.04% | 0.00% | 4,819 | 4,819 | 100.00% | 63,899,000 | Mar 31, 2023 |
MINT TOWER CAPITAL MANAGEMENT B.V. | 0.06% | 0.00% | 6,533 | 6,533 | 100.00% | 12,000 | Mar 31, 2023 |
GEODE CAPITAL MANAGEMENT, LLC | 0.16% | - | 18,559 | 18,559 | 100.00% | 249,432,000 | Mar 31, 2023 |
JPMORGAN CHASE & CO | 0.20% | - | 22,367 | 21,265 | 1929.67% | 301,000,000 | Mar 31, 2023 |
SCHONFELD STRATEGIC ADVISORS LLC | 0.27% | 0.00% | 30,100 | 30,100 | 100.00% | 399,126,000 | Mar 31, 2023 |
EVERSEPT PARTNERS, LP | 0.40% | 0.05% | 45,856 | 45,856 | 100.00% | 608,051,000 | Mar 31, 2023 |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 22.39% | 0.75% | 2,535,723 | 55,524 | 2.24% | 33,623,687,000 | Mar 31, 2023 |
MILLENNIUM MANAGEMENT LLC | 0.49% | 0.00% | 55,633 | 55,633 | 100.00% | 748,000 | Mar 31, 2023 |
As of Mar 31 2023, NewAmsterdam Pharma's biggest institutional seller is JANUS HENDERSON GROUP PLC. The company sold -0.56M shares of NAMS, valued at -.
Institutional New positions
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
ALYESKA INVESTMENT GROUP, L.P. | 2.55% | 0.03% | 289,265 | 289,265 | 100.00% | 3,835,654,000 | Mar 31, 2023 |
PARKMAN HEALTHCARE PARTNERS LLC | 1.02% | 0.33% | 115,000 | 115,000 | 100.00% | 1,524,900,000 | Mar 31, 2023 |
MILLENNIUM MANAGEMENT LLC | 0.49% | 0.00% | 55,633 | 55,633 | 100.00% | 748,000 | Mar 31, 2023 |
EVERSEPT PARTNERS, LP | 0.40% | 0.05% | 45,856 | 45,856 | 100.00% | 608,051,000 | Mar 31, 2023 |
SCHONFELD STRATEGIC ADVISORS LLC | 0.27% | 0.00% | 30,100 | 30,100 | 100.00% | 399,126,000 | Mar 31, 2023 |
GEODE CAPITAL MANAGEMENT, LLC | 0.16% | - | 18,559 | 18,559 | 100.00% | 249,432,000 | Mar 31, 2023 |
MINT TOWER CAPITAL MANAGEMENT B.V. | 0.06% | 0.00% | 6,533 | 6,533 | 100.00% | 12,000 | Mar 31, 2023 |
WOLVERINE ASSET MANAGEMENT LLC | 0.04% | 0.00% | 4,819 | 4,819 | 100.00% | 63,899,000 | Mar 31, 2023 |
MORGAN STANLEY | 0.00% | - | 503 | 503 | 100.00% | 6,670,000 | Mar 31, 2023 |
ATTICUS WEALTH MANAGEMENT, LLC | 0.00% | 0.00% | 166 | 166 | 100.00% | 2,202,000 | Mar 31, 2023 |
NewAmsterdam Pharma's largest new institutional shareholder by number of shares is ALYESKA INVESTMENT GROUP, L.P., purchased 289.26K shares, valued at $3.84B, as of undefined.
Institutional Sold Out
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
JANUS HENDERSON GROUP PLC | - | - | - | -563,119 | -100.00% | - | Mar 31, 2023 |
ALYESKA INVESTMENT GROUP, L.P. | - | - | - | -200,000 | -100.00% | - | Mar 31, 2023 |
TOWER RESEARCH CAPITAL LLC (TRC) | - | - | - | -88 | -100.00% | - | Mar 31, 2023 |
NewAmsterdam Pharma's largest sold out institutional shareholder by shares sold is JANUS HENDERSON GROUP PLC, sold -0.56M shares, valued at -, as of undefined.
NewAmsterdam Pharma Institutional Ownership Trends
Institutional Holdings Trend
Date | Holdings | Change % |
---|---|---|
31 Mar, 23 | 20 | 42.86% |
31 Dec, 22 | 14 | - |
As of 31 Mar 23, 20 institutions are holding NewAmsterdam Pharma's shares, representing an increase of 42.86% compared to the previous quarter.
Shares Outstanding Trend
Date | Shares Outstanding | Change % |
---|---|---|
31 Mar, 23 | 33,353,429 | -0.49% |
31 Dec, 22 | 33,516,836 | - |
NewAmsterdam Pharma (NAMS) has 33.35M shares outstanding as of 31 Mar 23, down -0.49% compared to the previous quarter.
Institutional Ownership Trend
Date | Ownership % | Change % |
---|---|---|
31 Mar, 23 | 100.00% | - |
31 Dec, 22 | 100.00% | - |
As of 31 Mar 23, NewAmsterdam Pharma is held by 100.00% institutional shareholders, representing a 0.00% growth compared to 31 Dec 22.
Institutional Increased Positions Trend
Date | Increased Positions | Change % |
---|---|---|
31 Mar, 23 | 4 | - |
31 Dec, 22 | - | - |
4 institutional shareholders have increased their position in NAMS stock as of 31 Mar 23 compared to - in the previous quarter (a 0.00% increase).
Institutional Reduced Positions Trend
Date | Reduced Positions | Change % |
---|---|---|
31 Mar, 23 | - | - |
31 Dec, 22 | - | - |
- institutional shareholders have reduced their position in NAMS stock as of 31 Mar 23 compared to - in the previous quarter (a 0.00% increase).
All Institutional Ownership Trend Data
Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
---|---|---|---|---|---|---|---|---|---|---|
31 Mar, 23 | 20 | 42.86% | 33,353,429 | -0.49% | 100.00% | - | 4 | - | - | - |
31 Dec, 22 | 14 | - | 33,516,836 | - | 100.00% | - | - | - | - | - |
NewAmsterdam Pharma Insider Shareholders Trades
Open Market Insider Trades
Open Market Insider Buys
Insider Sells
All Insider Owners Trades
The last insider sell of NewAmsterdam Pharma's stock was made by JONES WILLIAM A JR on May 03 2024, selling 815,598 shares at $10.70 per share (valued at $8.73M). The last insider buy of NAMS was made by Davidson Michael H. on Jun 24 2024, buying 5,000 shares at $17.26 per share (worth $86.31K).
NewAmsterdam Pharma Insider Ownership Trends
All Insider Trades Trend
Date | Buy | Sell | Buy/Sell Ratio |
---|---|---|---|
Q3 2024 | 1 | - | - |
Q2 2024 | 2 | 2 | 100.00% |
Q1 2024 | 12 | 3 | 400.00% |
Q4 2023 | - | 20 | - |
Q4 2022 | - | 2 | - |
1 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by NewAmsterdam Pharma's insiders, as of Q3 2024.
Open Market Insider Trades Trend
Date | Buy | Sell | Buy/Sell Ratio |
---|---|---|---|
Q3 2024 | - | - | - |
Q2 2024 | 1 | - | - |
Q1 2024 | 2 | 1 | 200.00% |
Q4 2023 | - | - | - |
Q4 2022 | - | - | - |
As of Q3 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of NewAmsterdam Pharma's stocks.
NewAmsterdam Pharma Peer Ownership
Ticker | Company |
---|---|
CYT | Cyteir Therapeutics, Inc. |
CGEM | Cullinan Oncology, Inc. |
PRTC | PureTech Health plc |
IVA | Inventiva S.A. |
MRUS | Merus N.V. |
MLYS | Mineralys Therapeutics, Inc. |
REPL | Replimune Group, Inc. |
JANX | Janux Therapeutics, Inc. |
CRNX | Crinetics Pharmaceuticals, Inc. |
GLUE | Monte Rosa Therapeutics, Inc. |
RZLT | Rezolute, Inc. |
PEPG | PepGen Inc. |
ANEB | Anebulo Pharmaceuticals, Inc. |
MOLN | Molecular Partners AG |
CMPX | Compass Therapeutics, Inc. |
ELYM | Eliem Therapeutics, Inc. |
NAMS Ownership FAQ
Who Owns NewAmsterdam Pharma?
NewAmsterdam Pharma is owned by institutional shareholders (100.00%), insiders (0.26%), and public (-0.26%). The largest institutional shareholder of NewAmsterdam Pharma is FRAZIER LIFE SCIENCES MANAGEMENT, L.P. (82.48% of total shares) and the top mutual fund owner is (0% of total shares).
Who are the major institutional shareholders of NewAmsterdam Pharma?
NewAmsterdam Pharma's major institutional shareholders are FRAZIER LIFE SCIENCES MANAGEMENT, L.P., BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC, RA CAPITAL MANAGEMENT, L.P., VIKING GLOBAL INVESTORS LP, and DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C). The top five shareholders own together 248.05% of the company's share outstanding.
How many NewAmsterdam Pharma shareholders are there?
As of Mar 2023, there are 20 institutional shareholders of NewAmsterdam Pharma.
What percentage of NewAmsterdam Pharma is owned by FRAZIER LIFE SCIENCES MANAGEMENT, L.P?
FRAZIER LIFE SCIENCES MANAGEMENT, L.P owns 9.34M shares of NewAmsterdam Pharma, representing 82.48% of the company's total shares outstanding, valued at $125.55B (as of Mar 2023).
What percentage of NewAmsterdam Pharma is owned by BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC?
As of Mar 2023, BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC holds 8.3M shares of NewAmsterdam Pharma (NAMS), compromising 73.29% of the company, valued at $110.06M.
What percentage of NewAmsterdam Pharma is owned by RA CAPITAL MANAGEMENT, L.P?
RA CAPITAL MANAGEMENT, L.P is the third largest holder of NewAmsterdam Pharma. The company owns 4M of the company's shares outstanding (worth $53.04B).